OBJECTIVES: It has been suggested that overexpression of HER2 in advanced cervical tumors can be considered an independent predictor of poor patient outcome. DESIGN AND METHODS: Employing PCR-RFLPs, we examined the distribution of HER2 Ile655Val (rs 1136201) genotypes and alleles in patients with advanced cervical cancer (n=109) and controls (n=220). RESULTS: Odds ratio (OR) for patients with advanced cervical cancer with the HER2 Val/Val homozygous or Val/Ile heterozygous state was 1.778 (95% CI=1.117-2.830, p=0.0176). We also observed an association of the HER2 Val/Val genotype with advanced cervical cancer in the patient group OR=3.706 (95% CI=1.061-12.950, p=0.0459). However, we did not find a significant association between the distribution of genotypes or alleles and cancer characteristics for the HER2 Ile655Val polymorphism. CONCLUSIONS: Our results indicate that the HER2 655Val variant may be associated with the incidence of advanced cervical cancer. Copyright 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
OBJECTIVES: It has been suggested that overexpression of HER2 in advanced cervical tumors can be considered an independent predictor of poor patient outcome. DESIGN AND METHODS: Employing PCR-RFLPs, we examined the distribution of HER2Ile655Val (rs 1136201) genotypes and alleles in patients with advanced cervical cancer (n=109) and controls (n=220). RESULTS: Odds ratio (OR) for patients with advanced cervical cancer with the HER2 Val/Val homozygous or Val/Ile heterozygous state was 1.778 (95% CI=1.117-2.830, p=0.0176). We also observed an association of the HER2 Val/Val genotype with advanced cervical cancer in the patient group OR=3.706 (95% CI=1.061-12.950, p=0.0459). However, we did not find a significant association between the distribution of genotypes or alleles and cancer characteristics for the HER2Ile655Val polymorphism. CONCLUSIONS: Our results indicate that the HER2 655Val variant may be associated with the incidence of advanced cervical cancer. Copyright 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
Authors: Rafał Watrowski; Dan Cacsire Castillo-Tong; Eva Schuster; Michael B Fischer; Paul Speiser; Robert Zeillinger Journal: Tumour Biol Date: 2015-12-14
Authors: Tung Nguyen Thanh; Bao Song Nguyen Tran; Ai Phuong Hoang Thi; Thang Tran Binh; Thong Ba Nguyen; Tam Le Minh; Quoc Huy Nguyen Vu; Thuan Dang Cong Journal: Asian Pac J Cancer Prev Date: 2021-01-01
Authors: Paola D Vermeer; Megan Bell; Kimberly Lee; Daniel W Vermeer; Byrant G Wieking; Erhan Bilal; Gyan Bhanot; Ronny I Drapkin; Shridar Ganesan; Aloysius J Klingelhutz; Wiljan J Hendriks; John H Lee Journal: PLoS One Date: 2012-01-18 Impact factor: 3.240
Authors: Yan Gao; Xiuwu Tang; Jieqin Cao; Rong Rong; Zhengmin Yu; Yang Liu; Yan Lu; Xiaowen Liu; Lei Han; Jiting Liu; Jun Zhang; Ming Xu; Fang Liu Journal: J Cancer Date: 2019-01-01 Impact factor: 4.207